

Correlation of Endothelial Nitric Oxide Synthase Gene Polymorphism (GG, TT and GT Genotype) with Proteinuria and Retinopathy in Type 2 Diabetic Patients

ALI MOMENI¹, MORTEZA HASHEMZADEH CHALESHTORI², SAEED SAADATMAND³, SOLEIMAN KHEIRI⁴

ABSTRACT

Background: Nephropathy is the most important leading cause of end stage renal failure in type 2 diabetic patients, so numerous studies were done to diagnose and evaluate risk factors of diabetic nephropathy (DN). Some gene polymorphisms may be associated with progression or regression of DN, so the aim of this study was to compare prevalence of eNOS gene polymorphism in diabetic patients with controls and its association with diabetic nephropathy.

Materials and Methods: In a cross-sectional study, 94 type 2 diabetic patients and 94 normal participants were enrolled. Patients without retinopathy were excluded from this study. For all of the patients, fasting blood sugar (FBS), 2 hours post-prandial (BS), Blood Urea Nitrogen (BUN), Creatinine (Cr), 24 hours urine

protein were measured in the case group. Endothelial nitric oxide synthetase gene polymorphism was evaluated in the case and control groups.

Results: There was no significant difference based on age and sex between patients in case and control groups. GG genotype of eNOS was less common in the patient group compared to control group. There was no difference between prevalence of TT, GT or GG genotype based on age and sex. There was no correlation between diabetic retinopathy or proteinuria and genotypes of eNOS.

Conclusion: The study showed that in type 2 diabetic patients, NOS gene polymorphism was more common compared to normal population; however, there is no correlation between this gene polymorphism and proteinuria or retinopathy in these patients.

Keywords: eNOS, Nephropathy, Retinopathy

INTRODUCTION

Diabetes mellitus is the most common cause of chronic renal failure and end stage renal disease worldwide. Microvascular and macrovascular complications of diabetes increase cardiovascular and overall mortality [1]. Diabetic nephropathy occurs in about 30%-35% of patients with type 1 and type 2 diabetic patients. After 5-10 years, some diabetic patients have micro albuminuria that means urine albumin is between 30 and 300 mg/day [2,3]. After additional 5-10 years, macroalbuminuria (urine albumin \geq 300 mg/day) developed and at the time being glomerular filtration rate (GFR) began to decline at the rate of 10-12 ml/year. Advanced glycosylation end products (AGES), oxidative stress and hypertension are the main causes of pathophysiologic changes that lead to diabetic nephropathy [4,5]. In addition, inhibition of vascular dilation factors that decrease production or release of EDRF (Endothelium-derived relaxing factor) also may have a role in the intonation or augmentation of diabetic nephropathy. Deficiency of nitrous oxide (NO) that is a vasodilation factor releasing by vascular endothelium also have a role in this regard. Decrease in the production of nitrous oxide synthase (NOS) may lead to decline of NO and vascular dilation. eNOS is an important enzyme that contribute in vascular homeostasis, so eNOS gen located on chromosome 7 and has 26 exon [6,7]. Gen polymorphism of ACE (Angiotensin Converting Enzyme) was reported to have a basic role in diabetic nephropathy [8]. DD allele of ACE gene has been reported with development and severity of diabetic nephropathy and more rapid progression to end stage renal disease [9]. For example in a study on 109 type 2 diabetic patients, there was a positive association between the D allele of the ACE polymorphism and proteinuria [10]. Although there is a controversy in the results of studies, so some studies with large sample size could not find this correlation in specific races [11]. Correlation between polymorphism of some allele of eNOS gene and diabetic

nephropathy and its severity has been also reported in other studies [12-14]. Based on our knowledge, there are a few studies in Iran especially in special races such as Lor on this issue. So, the aim of this study was to evaluate eNOS gene polymorphism with diabetic nephropathy and compare it among normal individuals.

MATERIALS AND METHODS

In a cross-sectional study, in Imam Ali clinic of Shahrekord, Iran, 100 diabetic patients and 100 normal participants were enrolled. All of the patients were among Lor tribe (Bakhtiari) that are one of the great and noble people of Iran. Inclusion criteria were: age greater than 40 year and presence of diabetes mellitus based on American Diabetes Association definition [15]. Diabetic patients with hypothyroidism, congestive heart failure and patients who had contraindication for consumption of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) were excluded from this study. All of the patients evaluated based on diabetic retinopathy and patients without retinopathy were excluded from the study. For all of the patients, Fasting Blood sugar (FBS), 2 hours post-prandial BS, Blood Urea Nitrogen (BUN), Creatinine (Cr), 24 hours urine protein were measured in case group by using Biotechnica Instruments (BT 3000) and Flame Photometer (Corning 480) Nyocard Reader II. Body weights, high Body Mass Index (BMI) with formula of body weight/height² were also measured in the patients. Consent form was filled in by all the patients.

DNA Extraction and Polymerase Chain Reaction Experiment

Three ml of blood sample was drawn from patients and stored in 5ml EDTA vacutainers at -20°C. Then DNA extraction was done using standard phenol/chloroform method and the final DNA pellet was dissolved in 20 μ l ddH₂O or TE. The quality of extracted

DNA was analyzed either by 0.7% agarose gel electrophoresis visualized by gel documentation imaging or UV spectrophotometry at 260/280 nm. Characteristics of forward and reverse primer were eNOS3-F: 5'-AGATGAAGGCAGGAGACAGTGG-3' and eNOS3-R: CCATCCACCCAGTCAATC-3' respectively.

Each PCR was performed in a 10 μ L reaction containing the following reagents: 25 ng genomic DNA, 1 μ L buffer (10 mM Tris-HCl {pH 8.3}, and 1.5 mM MgCl₂), 250 μ M MgCl₂, 1% DMSO (Sigma-Aldrich, St. Louis, MO), 200 μ M dNTPs, 0.5 μ M primer set, and 1U Taq DNA polymerase (sinagen, Iran). The condition of PCR cycles was included: initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation 94°C for 40 s, annealing 62°C for 90 s, and extension 72°C for 50 s, and a final extension at 72°C for 3 min. After confirming the achievement of the expected 262 bp band on 0.7% gel electrophoresis and visualization, the PCR products were subjected to MboI enzyme digestion and the products were then subjected to analysis on 12.5% polyacrylamide gel electrophoresis (PAGE). The expected restriction fragments of 162 bp and 100 bp were observed on the PAGE after visualization by silver staining. Sequence analysis of the PCR products was performed using the same primers as PCR by the ABI Big Dye Terminator Kit v.3.1 (Applied Biosystems, USA).

STATISTICAL ANALYSIS

For continuous variables, data were presented as means \pm SD as well as median; and for categorical ones, as frequency with percentage. Comparisons between groups were done using the Chi-square test for categorical variables and independent t-test for continuous ones. Kruskal-Wallis test was used to comparing the variables of interest among different genotype, because our data didn't meet the assumptions of the parametric analysis of variance. Statistical analysis was performed by SPSS and p-values <0.05 were statistically significant.

RESULTS

As 6 cases of each group could not follow the study, so this study continued and was done by 94 patients in each group. Age of the patients was 42 to 85 years with mean of 61.8 \pm 9.5 years. Thirty six (38.3%) of the patients were male and 58 (61.7%) were female. There was no significant difference based on age and sex between patients and control groups (p>0.05). Twenty six (27.7%) of the patients had proteinuria less than 150 mg (mean of 105.5mg) and the others had greater than 150 mg proteinuria per day. Some characteristics of the patients were mentioned in the [Table/Fig-1].

Frequency of eNOS genotype in the two groups of study was summarized in [Table/Fig-2]. Based on data in [Table/Fig-2], GG genotype was significantly less frequent in the patients compared to control group.

There is no difference between prevalence of TT, GT or GG genotype based on age and sex in two groups of the patients [Table/Fig-3,4]. Diabetic retinopathy did not have any correlation with genotypes of NOs. We did not find any correlation among TT, GT or GG genotypes and 24 hours urine protein, FBS and 2 hours postprandial blood sugar [Table/Fig-5].

DISCUSSION

The study showed that NOS synthase gene polymorphism in type 2 diabetes was more common compared to normal population but it was not found any correlation between this gene polymorphism and proteinuria or retinopathy in the patients.

T. Angeline in a study on 260 patients showed a correlation between NOS synthase and diabetes mellitus [16]. In a study on 400 diabetic patients, an association between 3 eNOS polymorphism (894G>T, -786T>C, and 27-bp-VNTR) and diabetic nephropathy was found [17]. Ze-jun Ma et al., in a meta-analysis found a significant association between the eNOS-4b/a polymorphism

Variable	Minimum	Maximum	Mean \pm SD
Age(year)	42	85	61.80 \pm 9.50
BMI(Kg/m ²)	20.48	42.97	28.60 \pm 4.52
SBP(mmHg)	100	210	146.60 \pm 24.95
DBP(mmHg)	60	120	87.18 \pm 13.61
Urine Protein(mg/day)	59	2438	589.80 \pm 627.20
FBS(mg/dl)	62	489	59 \pm 67
2HPPBS(mg/dl)	98	644	251.5 \pm 81.24
Serum Cr	0.50	5.90	1.41 \pm 0.799

[Table/Fig-1]: Some characteristics of the patients in the study

Genotype	Patients (N (%))	Control (N (%))	p
TT	58 (61.7)	62 (66)	0.047
GG	3 (3.2)	10 (10.6)	
GT	33 (35.1)	22 (23.4)	

[Table/Fig-2]: Prevalence of eNOS gen polymorphism in the patients and control groups.

Diabetic	TT (N (%))	GG (N (%))	GT (N (%))	p
Retinopathy	30 (58.8)	2 (3.9)	19 (37.3)	0.863
No Retinopathy	28 (65.1)	1 (2.3)	14 (32.6)	

[Table/Fig-3]: Gene polymorphism prevalence of the patients based on diabetic retinopathy.

Sample	Variable	TT (N (%))	GG (N (%))	GT (N (%))	p
Patients	Male	26 (72.2)	1 (2.8)	9 (25)	0.25
	Female	32 (55.2)	2 (3.4)	24 (41.4)	
Healthy	Male	27 (65.9)	5 (12.2)	9 (22)	0.891
	Female	35 (66)	5 (9.4)	13 (24.5)	

[Table/Fig-4]: Gene polymorphism prevalence of the patients and healthy groups based on sex.

Variable	TT	GG	GT	p
	Mean \pm SD (Median)	Mean \pm SD (Median)	Mean \pm SD (Median)	
Age	61.6 \pm 8.8 (61.5)	65 \pm 5 (61)	61.9 \pm 11.9 (61)	0.722
Urine protein	616.4 \pm 656.8 (358)	459 \pm 502.2 (221)	554.8 \pm 595.8 (399)	0.91
Serum Cr	1.44 \pm 0.81 (1.18)	1.16 \pm 0.07 (1.14)	1.39 \pm 0.78 (1.1)	0.85
FBS	153.5 \pm 55.8 (144)	169.6 \pm 50.5 (158)	168.1 \pm 85.5 (138)	0.81
2hppBS	253 \pm 70.2 (245)	256 \pm 23.39 (269)	248.5 \pm 101.8 (221)	0.53

[Table/Fig-5]: Association among some variables of interest and eNOS gene polymorphism in the patients group

and DN in Chinese population, but not in non-Asian populations [18]. Khamaisi showed that decreasing renal NOS activity at the progressive phase of diabetes is associated with a decline in neuronal NOS activity and protein expression [19]. In the Rippin et al., study on Type 1 diabetic patients, there was no correlation between NOs polymorphism and diabetic nephropathy, so their results have some similarity with our study [20]. El-Din reported that TT genotype of eNOS had association with increased risk of end stage renal disease in type 2 diabetic patients, so it may be a useful marker for identification of high risk diabetic patients [21]. Association of NOs gen polymorphism and retinopathy that is another microvascular complication of diabetes was reported by Bazzaz et al., [22]. Zintzaras et al., in a meta-analysis, showed that G894T NOs gen polymorphism is associated with diabetic nephropathy in East Asians patients [12]. In a systemic review, association of DN with eNOS 4b/a and T-786C gen polymorphism was reported by Dellamea et al., [23]. Bernhard et al., in their study

on type 1 and type 2 diabetic patients did not find that eNOS gene polymorphism plays a significant role in the development of diabetic nephropathy [24]. Huo P in Chinese population found an association between ACE and eNOS and diabetic nephropathy [25]. Rahimi in a study on 173 diabetic patients and 101 healthy cases found the significantly increasing risk of macroalbuminuria in the presence of either eNOS 4a or 894T allele, however, he could not find any association between concomitant presence of both alleles with increasing risk of macroalbuminuria [26]. In a study on albuminuric and normoalbuminuric diabetic patients by Cheema; in normoalbuminuric patients, eNOS -786 CC and C-b-G and C-b-T genotype were associated with lower anti-proteinuric response to ACEi agents. However, in macroalbuminuric patients, eNOS -786 CC, C-b-G and C-b-T and 27VNTR aa genotypes were associated with higher response to ACEi or ARB drugs [27]. In the patients with proliferative diabetic retinopathy, higher frequency of the eNOS was minor '4a' allele than in control group that it was found by Cilenšek [28]. Cheema showed that eNOS gene polymorphism increase responsiveness in type 2 diabetic patients without nephropathy and decrease response in microalbuminuric patients [27].

In a study by Corapcioglu in 97 Turkish diabetic foot ulcer patients and 102 controls, it was reported a significant association between eNOS alleles in patients with atherosclerotic heart disease, because GT-TT alleles were significantly higher than the GG alleles [29].

Cause of the discrepancy between above studies may be due to different ethnicity of the study populations.

LIMITATION

Cardinal limitation of the study was small sample size, so we recommended similar studies on larger number of the patients and evaluation of correlation between other gene polymorphisms and DM complications such as nephropathy, retinopathy, neuropathy and atherosclerosis.

CONCLUSION

In conclusion, the study showed more common prevalence of eNOS synthase gene polymorphism in type 2 diabetic patients compared to normal population; however, there is no correlation between this gene polymorphism and proteinuria or retinopathy in these patients.

ACKNOWLEDGEMENT

We thank all who support us both technically and financially in carrying out this research. The Grant No. of this manuscript is 1057 and its Ethical No. is 10-2-91.

REFERENCES

- Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. *Lancet*. 1998;352(9123):213-19. PubMed PMID: 9683226.
- Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. *The New England Journal of Medicine*. 1999;341(15):1127-33. PubMed PMID: 10511612.
- Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. *Journal of the American Society of Nephrology: JASN*. 2007;18(4):1353-61. PubMed PMID: 17329575.
- Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. *Current Pharmaceutical Design*. 2008;14(10):946-52. PubMed PMID: 18473844.
- Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. *The Journal of Biological Chemistry*. 2000;275(28):21177-84. PubMed PMID: 10801874.
- Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. *The Journal of Biological Chemistry*. 1993;268(23):17478-88. PubMed PMID: 7688726.

- Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. *Biochemical and Biophysical Research Communications*. 1994;198(3):1027-33. PubMed PMID: 7509596.
- Wiwanitkit V. ACE polymorphism and diabetic nephropathy. *Indian Journal of Nephrology*. 2010;20(2):118-19. PubMed PMID: 20835332. Pubmed Central PMCID: 2931131.
- Jeffers BW, Estacio RO, Reynolds MV, Schrier RW. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. *Kidney International*. 1997;52(2):473-7. PubMed PMID: 9264004.
- Viswanathan V, Zhu Y, Bala K, Dunn S, Shehala C, Ramachandran A, et al. Association between ACE gene polymorphism and diabetic nephropathy in South Indian patients. *JOP: Journal of the Pancreas*. 2001;2(2):83-7. PubMed PMID: 11867868.
- Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. *Journal of the American Society of Nephrology: JASN*. 2007;18(4):1284-91. PubMed PMID: 17376814.
- Zintzaras E, Papathanasiou AA, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. *Genetics in Medicine: Official Journal of the American College of Medical Genetics*. 2009;11(10):695-706. PubMed PMID: 19773668.
- Ezzidi I, Mtraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. *Journal of diabetes and its complications*. 2008;22(5):331-38. PubMed PMID: 18413207.
- Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. *Diabetes*. 2003;52(5):1270-75. PubMed PMID: 12716763.
- Association. AD. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33 Suppl 1:S62.
- Angeline T, Krithiga HR, Isabel W, Asirvatham AJ, Poornima A. Endothelial nitric oxide synthase gene polymorphism (G894T) and diabetes mellitus (type II) among South Indians. *Oxidative Medicine and Cellular Longevity*. 2011;2011:462607. PubMed PMID: 22110783. Pubmed Central PMCID: 3216347.
- Shoukry A, Shalaby SM, Abdelazim S, Abdelazim M, Ramadan A, Ismail MI, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. *Genetic Testing and Molecular Biomarkers*. 2012;16(6):574-79. PubMed PMID: 22313046.
- Ma ZJ, Chen R, Ren HZ, Guo X, Chen JG, Chen LM. Endothelial nitric oxide synthase (eNOS) 4b/a polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus: A meta-analysis. *Meta Gene*. 2014;2:50-62.
- Khamaisi M, Keynan S, Burszty M, Dahan R, Reinhartz E, Ovadia H, et al. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. *Nephron Physiology*. 2006;102(3-4):p72-80. PubMed PMID: 16319502.
- Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC. Nitric oxide synthase gene polymorphisms and diabetic nephropathy. *Diabetologia*. 2003;46(3):426-28. PubMed PMID: 12687343.
- El-Din Bessa SS, Hamdy SM. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. *Renal Failure*. 2011;33(9):878-84. PubMed PMID: 21854353.
- Bazzaz JT, Amoli MM, Pravica V, Chandrasegaran R, Boulton AJ, Larjani B, et al. eNOS gene polymorphism association with retinopathy in type 1 diabetes. *Ophthalmic Genetics*. 2010;31(3):103-07. PubMed PMID: 20565248.
- Dellamea BS, Pinto LC, Leitao CB, Santos KG, Canani LH. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. *BMC Medical Genetics*. 2014;15:9. PubMed PMID: 24433471. Pubmed Central PMCID: 3900462.
- Degen B, Schmidt S, Ritz E. A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. *Nephrology, dialysis, transplantation. Official publication of the European Dialysis and Transplant Association-European Renal Association*. 2001;16(1):185. PubMed PMID: 11209024.
- Huo P, Zhang D, Guan X, Mei Y, Zheng H, Feng X. Association between genetic polymorphisms of ACE & eNOS and diabetic nephropathy. *Mol Biol Rep*. 2015;42:27-33. PubMed PMID: 25227524.
- Rahimi Z, Rahimi Z, Shahvaisi-Zadeh F, Sadeghei S, Vessal M, Yavari N. eNOS 4a/b polymorphism and its interaction with eNOS G894T variants in type 2 diabetes mellitus: modifying the risk of diabetic nephropathy. *Disease Markers*. 2013;34(6):437-43. PubMed PMID: 23594559. Pubmed Central PMCID: 3810362.
- Cheema BS, Kohli HS, Sharma R, Bhansali A, Kullar M. Endothelial nitric oxide synthase gene polymorphisms and renal responsiveness to RAS inhibition therapy in type 2 diabetic Asian Indians. *Diabetes Research and Clinical Practice*. 2013;99(3):335-42. PubMed PMID: 23260854.

- [28] Cilensek I, Mankoc S, Globocnik Petrovic M, Petrovic D. The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. *Molecular Biology Reports*. 2012;39(6):7061-67. PubMed PMID: 22311033.
- [29] Corapcioglu D, Sahin M, Emral R, Celebi ZK, Sener O, Gedik VT. Association of the G894T polymorphism of the endothelial nitric oxide synthase gene with diabetic foot syndrome foot ulcer, diabetic complications, and comorbid vascular diseases: a Turkish case-control study. *Genetic Testing and Molecular Biomarkers*. 2010;14(4):483-88. PubMed PMID: 20642368.

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Nephrology, Nephrology Division of Internal medicine Department, Shahrekord University of Medical Sciences, Shahrekord, Iran.
2. Professor, Department of Human Genetics, Cellular and Molecular research center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
3. Internist, Department of Internal Medicine Department, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4. Associate Professor, Department of Biostatics, Clinical Biochemistry Research Center, Shahrekord University of Medical Sciences, Iran.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Morteza Hashemzadeh Chaleshtori,
Professor of Human Genetics, Cellular and Molecular Research Center,
Shahrekord University of Medical Sciences, Shahrekord, Iran.
E-mail:mchalesh@yahoo.com

Date of Submission: **May 22, 2015**

Date of Peer Review: **Jun 29, 2015**

Date of Acceptance: **Jul 27, 2015**

Date of Publishing: **Feb 01, 2016**

FINANCIAL OR OTHER COMPETING INTERESTS: None.